<DOC>
	<DOCNO>NCT00673777</DOCNO>
	<brief_summary>The purpose study evaluate safety time progression HLA-A*0201 restrict epitope peptide URLC10 , VEGFR1 VEGFR2 emulsify Montanide ISA 51 .</brief_summary>
	<brief_title>Histocompatibility Leukocyte Antigen ( HLA ) -A*0201 Restricted Peptide Vaccine Therapy Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>URLC10 identify cancer specific molecule especially non small cell lung cancer use genome-wide expression profile analysis cDNA microarray technique . We determine HLA-A*0201 restrict epitope peptide derive molecule . We also tend use peptide target tumor angiogenesis . VEGF receptor 1 2 essential target tumor angiogenesis , identify peptide derive receptor significantly induce effective tumor specific CTL response vitro vivo . According finding , trial , evaluate safety , immunological clinical response peptide . Patients vaccinate twice week 8 week . On vaccination day , URLC10-117 peptide ( 1mg ) , VEGFR1 peptide ( 1mg ) VEGFR2 peptide ( 1mg ) mixed Montanide ISA 51 administer subcutaneous injection . Repeated cycle vaccine administer patient develop progressive disease unacceptable toxicity , whichever occur first . In phase I study , evaluate safety tolerability peptide vaccine . In follow phase II study , evaluate immunological clinical response vaccine therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Disease characteristic Advanced recurrent non small cell lung cancer Second line later therapeutic status Patient characteristic ECOG performance status 02 Life expectancy &gt; 3 month HLAA*0201 Laboratory value follow 2000/mm3 &lt; WBC &lt; 15000/mm3 Platelet count &gt; 100000/mm3 Bilirubin &lt; 3.0mg/dl Asparate transaminase &lt; 150IU/L Alanine transaminase &lt; 150IU/L Creatinine &lt; 3.0mg/dl Able willing give valid write informed consent Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) Breastfeeding Active uncontrolled infection Unhealed external wound Concurrent treatment steroid immunosuppressing agent Prior chemotherapy , radiation therapy , immunotherapy within 4 week Uncontrolled brain and/or intraspinal metastasis Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>HLA-A*0201</keyword>
	<keyword>Peptide Vaccine</keyword>
	<keyword>URLC10</keyword>
	<keyword>VEGFR1</keyword>
	<keyword>VEGFR2</keyword>
</DOC>